

Highlights in hepatocellular carcinoma

Grace Li

Editorial office, Chinese Clinical Oncology, Hong Kong, China

Corresponding to: Grace Li. Editorial office, Chinese Clinical Oncology (CCO), FLAT A, 9/F Gold Shine Tower, 346-348 Queen's Road Central, Sheung Wan, Hong Kong, China. Email: editor@thecco.net.



Submitted May 06, 2013. Accepted for publication Jun 10, 2013.

doi: 10.3978/j.issn.2224-5820.2013.07.04

Scan to your mobile device or view this article at: <http://www.amepc.org/apm/article/view/2451/3343>

We are glad to tell you that our sister journal *Chinese Clinical Oncology* is going to launch a special issue on Hepatocellular Carcinoma (HCC) in the September 2013, which studies HCC in different specific circumstance given due consideration. Our Guest Editor for this special issue is Dr Ghassan K. Abou-Alfa, from Memorial Sloan-Kettering Cancer Center, New York, USA.

The *Chinese Clinical Oncology* (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO), the official publication of Society for Translational Cancer Research (STCR) and endorsed by Chinese Society of Clinical Oncology (CSCO), publishes articles that describe new findings in the field of oncology, provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field, while providing practical up-to-date information on diagnosis, prevention, and treatment of cancer. To that end, CCO is dedicated to translating the latest research developments into best multimodality practice.

In this special issue, known experts worldwide in related field are getting together to share their knowledge in terms of diagnosis and treatment of HCC. Apart from the up-to-date review in HCC, you will also be able to learn the status of HCC in a wide geographic background including Asia, Europe and America. We hope you will enjoy this special issue.

The outline for this special issue is as follows:

❖ Preface

Ghassan K. Abou-Alfa

Memorial Sloan-Kettering Cancer Center, New York, USA

❖ Hepatitis risk factors

Maya Gambarin

Section of Gastroenterology, Memorial Sloan-Kettering Cancer Center, New York, USA

❖ Scoring and staging

Alan Venook

Professor of Clinical Medicine, Division of Hematology Oncology, University of California San Francisco, San Francisco, CA, USA

❖ Cirrhosis management

Roniel Cabrera

Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, FL, USA

❖ Surgical and transplant interventions

Ioannis Konstantinidis and Yuman Fong

Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA

❖ Local therapies

Jeffrey Geschwind

Director of Vascular and Interventional Radiology, Interventional Radiology Center, Johns Hopkins Hospital, Baltimore, MD, USA

❖ Systemic therapy for HCC

James Harding and Ghassan K. Abou-Alfa

Section of Gastrointestinal Cancer, Memorial Sloan-

Kettering Cancer Center, New York, USA

❖ **Status of HCC in China**

Shuki Qin
Chair of Chinese Society of Clinical Oncology (CSCO);
Deputy director of People's Liberation Army (PLA) 81
Hospital (Nanjing, China); Director of Cancer Center of
Chinese PLA

❖ **Status of HCC in Japan**

Masafumi Ikeda
Division of Hepatobiliary and Pancreatic Oncology,
National Cancer Center Hospital East, Kashiwa, Chiba,
Japan

❖ **Status of HCC in Korea**

HooGuen Chun
Comprehensive Cancer Institute, Catholic University of
Korea, 222 Banpo-daero, Seocho-gu, Seoul, Korea

❖ **Status of HCC in Egypt**

Ashraf Abdelaziz
Section of Gastroenterology, Cairo University, Egypt

❖ **Status of HCC in India**

G. S. Bhattacharyya
Dept. of Medical Oncology, FORTIS Hospitals, Anandapur,
EM Bypass, Kolkata, India, AMRI, Kolkata, India

❖ **Status of HCC in USA**

Andrew Zhu
Liver Cancer Research, Massachusetts General Hospital
Cancer Center, Boston, MA, USA

❖ **Status of HCC in Europe**

Tim Meyer
UCL Cancer Institute, University College London,
London, United Kingdom

Acknowledgements

Disclosure: The author declares no conflict of interest.

Cite this article as: Li G. Highlights in hepatocellular carcinoma. *Ann Palliat Med* 2013;2(3):156-157. doi: 10.3978/j.issn.2224-5820.2013.07.04